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http://www.biomedcentral.com/1471-2296/14/123RESEARCH ARTICLE Open AccessWhich patient and treatment factors are related
to successful cardiovascular risk score reduction
in general practice? Results from a randomized
controlled trial
Ans H Tiessen1*, Andries J Smit2, Jan Broer3, Klaas H Groenier1 and Klaas Van der Meer1Abstract
Background: Cardiovascular disease is a leading cause of death. It is important to identify patient and treatment
factors that are related to successful cardiovascular risk reduction in general practice. This study investigates which
patient and treatment factors are related to changes in cardiovascular risk estimation, expressed as the Systematic
Coronary Risk Evaluation (SCORE) 10 year risk of cardiovascular mortality.
Methods: 179 general practice patients with mild-moderately elevated cardiovascular risk followed a one-year
programme which included structured lifestyle and medication treatment by practice nurses, with or without
additional self-monitoring. From the patient and treatment data collected as part of the “Self-monitoring and
Prevention of RIsk factors by Nurse practitioners in the region of Groningen” randomized controlled trial (SPRING-RCT),
the contribution of patient and treatment factors to the change in SCORE was analysed with univariate and
multivariate analyses.
Results: In multivariate analyses with multiple patient and treatment factors, only SCORE at baseline, and addition of or
dose change in lipid lowering or antihypertensive medications over the course of the study were significantly related
to change in SCORE.
Conclusions: Our analyses support the targeting of treatment at individuals with a high SCORE at presentation.
Lipid lowering medication was added or changed in only 12% of participants, but nevertheless was significantly
related to ΔSCORE in this study population. Due to the effect of medication in this practice-based project, the
possible additional effect of the home monitoring devices, especially for individuals with no indication for
medication, may have been overshadowed.
Trial registration: trialregister.nl NTR2188
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Cardiovascular disease (CVD) is a leading cause of death
both worldwide (29% of all deaths, 2004) [1] and in
the Netherlands (28% of all deaths, 2011; Statistics
Netherlands). The previously reported “Self-monitoring
and Prevention of RIsk factors by Nurse practitioners
in the region of Groningen” randomized controlled trial
(SPRING-RCT) assessed Systematic Coronary Risk Evalu-
ation (SCORE) 10 year risk of cardiovascular mortality in
individuals with a mild to moderately elevated cardiovas-
cular risk [2,3]. This study demonstrated that one year of
combined lifestyle and medication treatments by practice
nurses led to a significant decrease in cardiovascular risk
(Figure 1) and showed that this effect was not increased
with self-monitoring.
As treatment goals for cardiovascular risk factors are
often not achieved, [4,5] it is important to identify pa-
tient and treatment factors that are related to successful
cardiovascular risk reduction in clinical practice. Strat-
egies that are generally assumed to be effective include
individualized risk assessment, risk communication and
goal setting, and these are typically incorporated into
national and international guidelines as well as research
projects [6-8]. These elements formed part of the treat-
ment in both study groups of the SPRING-RCT. The
main difference between the treatment groups in this
study was the use of self-monitoring as a basis for feed-
back and counselling (intervention group). In addition,
previous analysis of this data has revealed that total
consultation time and the use of antihypertensive medica-
tion were higher in the intervention group [3].Figure 1 Distribution of ΔSCORE for all participants after one year of
means that the estimated 10-year cardiovascular risk decreased afterThe objective of this paper is to investigate which
patient and treatment factors are related to changes in
cardiovascular risk estimation in individuals with a mild
to moderately elevated cardiovascular risk and who are
enrolled in a programme of structured lifestyle and medi-
cation counselling with or without self-monitoring.
Methods
For the purposes of this investigation, patient and treat-
ment data collected as part of the SPRING-RCT were
further analysed. Between June 2008 and August 2009
randomly selected individuals from 20 general practices
were invited for a screening. Men aged 50–75 years and
women aged 55–75 years were enrolled in the study if
they met the following criteria: 1) Estimated SCORE
10-year risk of cardiovascular mortality ≥5% [2]; 2) at
least one treatable cardiovascular risk factor (smoking,
hypertension, lack of physical activity or overweight);
and, 3) no history of CVD, diabetes mellitus, thyroid
dysfunction or an estimated life expectancy <2 years.
Patients were randomised into control and intervention
groups. All patients received standard treatment according
to the 2006 Dutch general practitioner’s guidelines, [6]
from specially trained practice nurses. The intervention
group additionally received counselling based on self-
monitoring at home with pedometers, weighing scales
and/or blood pressure monitoring devices. After one
year data from 179 participants were collected and analysed.
The primary outcome was the SCORE 10-year risk of
fatal CVD which is based on sex, age, blood pressure,
lipid levels and smoking status and mean change in thiscardiovascular risk management (a negative number for ΔSCORE
one year). The outlier was not included in subsequent analyses.
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group −1,63%; intervention group −1,79%). The SPRING
study was approved by the Medical Ethics Review
Committee of the University Medical Centre Groningen
(reference number 2007/232). For more detailed informa-
tion on study design and outcomes, see Tiessen et al. [3].
Statistical analysis
General Linear Modelling was used for univariate (indi-
vidual patient and treatment factors as independent vari-
ables) and multivariate (all patient and treatment factors
as independent variables) analyses, with the ΔSCORE as
the dependent variable. For a description of all analysed
variables see Table 1. Figure 1 shows one outlier with
respect to the distribution of the ΔSCORE, which was
removed from further analyses. All variables from the
univariate analyses were included in the multivariate
model (not only the significant ones), in order to deter-
mine which factors contribute to the ΔSCORE and to
what extent. In addition to investigating the effect of
consultation time on ΔSCORE, we analysed the relative
contribution of consultation time and different factors,
which are: 1) the self-monitoring devices (home blood








Sex (male/female) n (%) male Sex o
Age (years) Mean (SD) Age o
Level of education (4 levels) n (%) Self-re
SCORE at baseline (%) Mean (SD) Estim
at bas
Treatment characteristics:
Treatment group (control/intervention) n (%) interv. Treatm
with (
Consultation time (minutes) Mean (SD) Total
of the
Treatment intensity (%) Mean (SD) % of
Home blood pressure device Was a
Home weighing scale Was a
Home pedometer Was a
More than one visit for smoking Was s
New/changed medication for cholesterol Was m
New/changed medication for hypertension Was m
*The independent variables are described in the following manner: variable (descrip
the variables with categories yes/no: these are not described any further and the g
**adapted Systematic Coronary Risk Evaluation, as used in the 2006 Dutch General2) more than one visit for smoking cessation; and 3) treat-
ment intensity (percentage of indicated treatment goals for
which treatment had actually been started) on ΔSCORE.
Data from participants with missing data values were
compared with data from participants with complete
data sets and plots of residual vs. predicted values and
QQ plots of the residuals were visually analysed to check
the assumptions on normal distribution. A p-value <0.05
was considered significant. We used IBM SPSS statistical
software version 20.
Results
Total consultation time (i.e. total number of minutes
participants spent visiting the practice nurse) was signifi-
cantly related to a decrease in SCORE in the univariate
analysis (Table 2): The value of B=−0.012 (95% CI −0.018,
-0.005) corresponds to a decrease in SCORE of 0.012%
with every extra minute of consultation time over the
course of the study. The treatment intensity, more than
one visit for smoking cessation and the use of the self-
monitoring devices (except the pedometer) were also
significantly related to a decrease in SCORE in the univar-
iate analyses (Table 1). However, when these factors were
analysed together, only the use of the self-monitoringthe analysis
nation
ated 10-year cardiovascular mortality risk according to SCORE** after
ear minus estimated 10-year cardiovascular mortality risk at baseline
tive numbers indicate a decrease in estimated risk)
f participant
f participant
ported highest level of education of participant
ated 10-year cardiovascular mortality risk according to SCORE**
eline of participant
ent group into which participant was randomised:
intervention group) or without (control group) self-monitoring
duration (in minutes) of all visits to practice nurse in the framework
SPRING study
indicated treatment goals for which treatment had actually been started
home blood pressure device used as part of the SPRING study?
home weighing scale used as part of the SPRING study?
home pedometer used as part of the SPRING study?
moking cessation discussed at more than one visit to the practice nurse?
edication for cholesterol newly prescribed or the dosage altered?
edication for hypertension newly prescribed or the dosage altered?
tion of categories/unit of measurement) n (%) category/Mean (SD), except for
iven results are n (%) of “yes”.
Practitioner’s Guideline on cardiovascular risk management.
Table 2 The relationship between factors affecting consultation time and ΔSCORE
n (%) unless
otherwise indicated
n missing Univariate analysis Multivariate analysis
B 95% CI R2 (adj. R2) B 95% CI
Consultation time (minutes) Mean (SD) 97 (64) 3 −0.012 −0.018, −0.005* 0.074 (0.069) −0.005 −0.014, 0.004
Treatment intensity (%) Mean (SD) 79 (24) 1 −0.024 −0.040, −0.007* 0.043 (0.037) −0.018 −0.035, 0.000
Home blood pressure device 43 (24) 0 −1.557 −2.484, −0.630* 0.059 (0.053) −1.188 −2.186, −0.191*
Home weighing scale 42 (24) 0 −1.238 −2.183, −0.292* 0.037 (0.031) −0.630 −1.874, 0.614
Home pedometer 30 (17) 0 −0.940 −2.024, 0.144 0.016 (0.011) 0.647 −0.936, 2.230
More than one visit for smoking 27 (15) 0 −1.231 −2.356, −0.105* 0.026 (0.020) −0.998 −2.121, 0.126
95% CI= 95% confidence interval of B, R2 = explained variance, adj.= adjusted. *= significant, Multivariate analysis R2= 0.130 (adjusted R2= 0.099).
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crease in SCORE (B=−1.188 (95% CI −2.186, -0.191)).
In this study the only patient factor shown to be
significantly related to a decrease in SCORE in both
uni- and multi-variate analysis (multivariate analysis,
B=−0.246 (95% CI −0.363, -0.128)) was the SCORE at
baseline (Table 3). All studied treatment factors were
significantly related to a decrease in SCORE in the
univariate analysis, except treatment group and pedometer.






Sex (male/female) n (%) male 123 (69) 0
Age (years) Mean (SD) 65 (5) 0
Level of education (4 levels) n (%): 2
1: No education or only primary education** 17 (10)
2: Lower secondary education 74 (42)
3: Higher secondary education 47 (26)
4: College or university 38 (21)
SCORE at baseline (%) Mean (SD) 8.6 (4.1) 0
Treatment characteristics:
Treatment group (control/intervention) n (%) interv. 89 (50) 0
Consultation time (minutes) Mean (SD) 97 (64) 3
Treatment intensity (%) Mean (SD) 79 (24) 1
Home blood pressure device 43 (24) 0
Home weighing scale 42 (24) 0
Home pedometer 30 (17) 0
More than one visit for smoking 27 (15) 0
New/changed medication for cholesterol 22 (12) 0
New/changed medication for hypertension 46 (26) 0
95% CI= 95% confidence interval of B, R2 = explained variance, adj.=adjusted. *= signifactors, only added/changed medication for hypertension
and cholesterol remain significant, B= −1.051 (95% CI
−2.039, -0.062) and B= −2.067 (95% CI −3.247, -0.886),
respectively.
There were very few missing data values and only age
was significantly different between participants with
and without missing values, median age 69.5 years and
65.0 years for participants with and without missing
values, respectively (p=0.02, Mann–Whitney U test). No
abnormalities were found with respect to the assumptions.nship to ΔSCORE
Univariate analysis Multivariate analysis
B 95% CI R2 (adj. R2) B 95% CI
0.246 −0.638, 1.131 0.002 (−0.004) 0.666 −0.349, 1.681
0.012 −0.063, 0.087 0.001 (−0.005) 0.038 −0.041, 0.118
0.015 (−0.003)
1.012 −0.458, 2.482 0.322 −1.003, 1.648
1.183 −0.363, 2.730 0.621 −0.812, 2.055
1.157 −0.438, 2.751 −0.213 −1.695, 1.270
−0.226 −0.321, −0.130* 0.111 (0.105) −0.246 −0.363, −0.128*
−0.387 −1.203, 0.429 0.005 (−0.001) 0.722 −0.223, 1.667
−0.012 −0.018, −0.005* 0.074 (0.069) 0.000 −0.009, 0.009
−0.024 −0.040, −0.007* 0.043 (0.037) −0.009 −0.026, 0.008
−1.557 −2.484, −0.630* 0.059 (0.053) −0.489 −1.474, 0.496
−1.238 −2.183, −0.292* 0.037 (0.031) −1.138 −2.356, 0.080
−0.940 −2.024, 0.144 0.016 (0.011) 0.115 −1.345, 1.576
−1.231 −2.356, −0.105* 0.026 (0.020) −0.644 −1.712, 0.424
−3.426 −4.559, −2.292* 0.168 (0.163) −2.067 −3.247, −0.886*
−2.195 −3.071, −1.320* 0.122 (0.117) −1.051 −2.039, −0.062*
ficant; **=reference category, Multivariate analysis R2= 0.360 (adjusted R2= 0.298).
Tiessen et al. BMC Family Practice 2013, 14:123 Page 5 of 7
http://www.biomedcentral.com/1471-2296/14/123Discussion
Summary of main findings
The goal of this paper was to investigate which patient
and treatment factors are related to changes in cardio-
vascular risk estimation. Our results show that in the
univariate analysis, the consultation time is significantly
related to the ΔSCORE. However, when the analysis in-
cludes the use of separate devices and treatment factors,
only the use of the home blood pressure device was
significantly related to the ΔSCORE, and consultation
time was not significant anymore. The analyses with all
studied patient- and treatment factors show that ΔSCORE
is related to both baseline SCORE and changed/added
antihypertensive and lipid lowering medication in the
multivariate analysis.
Comparison with existing literature
Diabetes prevention and smoking cessation studies have
demonstrated that success is more likely in patients who
are closely monitored [9,10]. It is therefore possible that
a similar positive effect may be seen in this study; namely
a reduction in ΔSCORE in the patients using self-
monitoring devices and being, therefore, potentially more
intense follow-up with more consultation time. However,
the significant effect of consultation time on ΔSCORE is
not shown in our multivariate results.
A possible explanation for the influence of the use of
the home blood pressure device on ΔSCORE (Table 2) is
that this is the only self-monitoring device used in this
study that is directly related to one of the components
of SCORE risk estimation. In contrast, use of the weighing
scale and pedometer for the monitoring of weight and
physical activity are not part of the SCORE calculation.
Furthermore, the home blood pressure device and the
home weighing scale were each used by a large number
of participants (24%) whereas the pedometer was only
used by 17% of the participants and is therefore unlikely
to have a significant effect on the total ΔSCORE of all
participants. The failure to show a significant relation-
ship between ΔSCORE and the number of smoking-
related visits made during the study despite the direct
effect of this variable on a risk factor included in the
SCORE calculation could similarly be explained by the
small fraction of subjects in this category (15%). In this
study treatment intensity, which may reflect the motivation
of the patient was not significantly related to the overall
decrease in SCORE seen in the multivariate analysis.
The second part about comparison with existing litera-
ture focusses on the analyses with all studied patient and
treatment factors. These analyses show that ΔSCORE
is related to both baseline SCORE and changed/added
antihypertensive and lipid lowering medication in the
multivariate analysis, with an explained variance of 36%
(Table 3). This effect was not related to the fact that onlyparticipants with a substantially elevated cardiovascular
risk were advised to take medication, as both medica-
tion data and baseline SCORE were independently re-
lated to ΔSCORE. The positive effect of lipid lowering
medication on cardiovascular risk reported here is par-
ticularly remarkable given that only 12% of patients
were newly prescribed with or received an altered dose
of lipid lowering medication over the course of this
study. The effect of anti-hypertensives on cardiovascular
risk is less surprising, because 26% of participants received
a new prescription or altered dose of this medicine during
the study. These findings combined with the relatively low
cost of the medications, [11] serve to confirm the import-
ant role of statins and antihypertensives as part of a car-
diovascular risk reduction programme [12,13].
We expected that participants with hypertension would
receive either home monitoring as well as (added/changed
antihypertensive) medication or only medication in the
intervention and control groups, respectively, and that
home blood pressure monitoring would not be used in
patients who were not receiving medication. Our results
show an unexpectedly high rate of home blood pressure
monitoring in patients who were not receiving added/
changed antihypertensive medication: Of the 178 par-
ticipants included in this analysis 27 had used both
medication and home monitoring for their blood pres-
sure, 19 only medication, 16 only home monitoring and
116 made use of neither of these. This may reflect the
individualized nature of the therapy in this practice-
based RCT and may have influenced the relation between
home blood pressure monitoring and ΔSCORE. Com-
bined with the fact that treatment for hypercholesterol-
emia was the same in both control and intervention
groups, the use of home blood pressure monitoring by
patients in both groups may go some way to explaining
the lack of significant difference between groups in terms
of ΔSCORE.
With respect to the SCORE at baseline the European
Guidelines on CVD prevention in clinical practice state
that “the higher the risk the greater the benefit from
preventive efforts” [7]. Targeting high risk individuals is
also recommended by the Cochrane review on multiple
risk factor interventions for primary prevention of cor-
onary heart disease [14]. Our analyses confirm that the
main focus of cardiovascular risk reduction should be
the population with the highest risk levels. However, the
magnitude of the effect in these participants in our study
may be partly due to the regression to the mean-effect.
Strengths and limitations
Because we intended to analyse which factors are related
to ΔSCORE to what extent, and not to predict ΔSCORE,
we included all variables from the univariate analyses in
the multivariate model and not only the ones found to
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not be interpreted as a clinical decision rule, but might
help clinicians substantiate the focus of cardiovascular
risk management at their practices [15].
The current study took place in the practice setting
meaning that the results can be easily translated into
general practice treatment strategies. The sample popu-
lation, with a mild-moderately elevated cardiovascular
risk, is a heterogeneous group with respect to individual
risk factors, treatment goals and therapy chosen by each
participant in cooperation with his/her practice nurse.
Most known factors influencing CVD risk were col-
lected for the SPRING-RCT and included in the analyses.
Whilst it has been shown that psychological factors such
as stress, motivation, self-efficacy and received help may
have an impact on cardiovascular risk and risk factor re-
duction, these aspects were not assessed in this study
[10,16]. All studied variables were present in a consider-
able proportion in the study population, as can be seen
in Tables 2 and 3. However, as the data were collected
as part of the SPRING-RCT, the sample size was calcu-
lated for the primary outcome of this RCT and not for
the analyses of this paper. Finally, the research staff who
did the measurements at follow-up was not blinded.
However, SCORE was not directly measured, so this in-
fluence might be limited.
Interpretation of our results is facilitated by the use of
unstandardized coefficients and their 95% confidence
intervals which clearly show the size of the effect on the
ΔSCORE, given a certain value of the specific independ-
ent variable.
We did not collect data on long term outcomes re-
garding cardiovascular morbidity and mortality, because
our endpoint is the ΔSCORE where SCORE is a tool for
risk stratification. The adapted SCORE, based on the
Dutch situation, which was used in the 2006 Dutch
General Practitioner’s Guideline on cardiovascular risk
management as well as in this study, appears to over-
estimate cardiovascular mortality [17]. This is possibly
due to the decline in cardiovascular mortality. This over-
estimation was reported in many European countries
[18-21] but not in all [22,23]. The significant effect of
medication on the ΔSCORE probably reflects the direct
effect of lipid levels and blood pressure on the parame-
ters included in the calculation of SCORE. Because of this,
it is important that the ΔSCORE reported here should not
be considered as an exact predictor of decreased mortality
risk, but as an indicator for cardiovascular risk reduction.
Conclusions
For successful cardiovascular risk management, defined
as greatest feasible reduction in the ΔSCORE at general
practice level, it is clear that treatment should be focused at
individuals with high SCORE at presentation. Medication(lipid lowering and antihypertensive) was independently
related to a significant decrease in estimated cardiovas-
cular risk, even though lipid lowering medication was
added/changed in only 12% of the participants. It is also
worthy of note that lipid lowering medication was
the only intervention factor for which no intensive/
self-monitoring treatment alternative was offered in
the intervention group. The SPRING-RCT was set up
to investigate whether counselling based on home moni-
toring would have an additional effect on the estimated
cardiovascular risk. Due to the effect of medication in
this practice-based project, the possible additional effect
of the home monitoring devices, especially for individ-
uals with no indication for medication, may have been
overshadowed. However, based on these results we rec-
ommend that for optimal risk reduction in general prac-
tice treatments (including prescription of medications
when indicated and agreed with by the patient) for car-
diovascular risk be targeted at high-risk individuals.
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